Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of MK-2118, a Small-Molecule Agonist of STING.

ACS medicinal chemistry letters·2026
Same author

Significant aggravation of pre-existing myalgic encephalomyelitis/chronic fatigue syndrome following proton beam therapy for sphenoid wing meningioma: case report.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Mid- and long-term results of primary vs. secondary total elbow arthroplasty after index intra-articular fracture of the distal humerus in the elderly.

Journal of shoulder and elbow arthroplasty·2026
Same author

Outcomes after contact and distance elbow arthrodesis: a retrospective cohort study.

BMC musculoskeletal disorders·2026
Same author

Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modeling.

Biochemistry and biophysics reports·2026
Same author

[Calcaneal fractures-Current status and treatment approaches].

Unfallchirurgie (Heidelberg, Germany)·2026

Related Experiment Video

Updated: Feb 20, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.2K

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.

Johnny Kopinja1, Raquel S Sevilla1, Diane Levitan1

  • 1Merck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, 07033, USA.

Scientific Reports
|October 25, 2017
PubMed
Summary

Targeting isocitrate dehydrogenase 1 (IDH1) mutations in glioma with selective inhibitors reduced 2-hydroxyglutarate (2-HG) and improved survival in patient models, suggesting a new therapeutic avenue.

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K

Related Experiment Videos

Last Updated: Feb 20, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.2K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Isocitrate dehydrogenase 1 (IDH1) mutations are common in human glioma.
  • Current radiotherapy treatments for glioma can cause significant morbidities.
  • There is a need for alternative, brain-penetrant therapies targeting IDH1 mutations.

Purpose of the Study:

  • To evaluate the therapeutic potential of IDH1 mutant-selective inhibitors.
  • To assess the impact of intracranial 2-hydroxyglutarate (2-HG) inhibition in IDH1 mutant glioma models.

Main Methods:

  • Utilized IDH1 mutant patient-derived glioma cell line models.
  • Administered IDH1 mutant-selective inhibitors.
  • Measured intracellular 2-HG levels in vitro and in vivo.
  • Assessed glioma cell proliferation and animal survival.

Main Results:

  • Inhibitor treatment decreased intracellular 2-HG levels in IDH1 mutant models.
  • In vitro cell proliferation was unaffected by 2-HG inhibition.
  • Significant survival benefits were observed in vivo with IDH1 mutant-selective inhibitors.
  • Not all IDH1 mutant glioma models responded to treatment despite near-complete 2-HG inhibition.

Conclusions:

  • Brain-penetrant IDH1 mutant-selective inhibitors can reduce 2-HG levels in glioma.
  • Disrupting 2-HG production offers potential survival benefits for IDH1 mutant glioma patients.
  • Further research is needed to understand differential treatment responses.